The SchrOedinger Building
Oxford Science Park
Oxford OX4 4GE
44 18 6581 8941
|Prof. Andrew L. Hopkins DPHIL, FRSE FRSC||Founder, CEO & Exec. Director||670,26k||N/A||1973|
|Mr. Ben R. Taylor||CFO, Chief Strategy Officer & Exec. Director||469,83k||N/A||1977|
|Dr. Garry Pairaudeau Ph.D.||Chief Technology Officer||N/A||N/A||1967|
|Dr. David Hallett Ph.D.||Chief Scientific Officer||N/A||N/A||1971|
|Dr. Michael Krams M.D.||Chief Quantitative Medicine Officer||N/A||N/A||1961|
|Ms. Margo Mosley||VP of Facilities & Operations||N/A||N/A||N/A|
|Ms. Eileen Jennings-Brown||Chief Information Officer||N/A||N/A||N/A|
|Ms. Sara Sherman||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Dan Ireland||VP of Legal||N/A||N/A||N/A|
|Mr. Oliver Stohlmann||VP of Communications||N/A||N/A||N/A|
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. It also focuses on discovery and development of small molecule drug candidates. The company's platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Exscientia plcs ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.